# Lobe Sciences sickle cell drug funding

> Live situation record from CLSTR: https://clstr.news/situations/lobe-sciences-sickle-cell-drug-funding
> Updated: 2026-08-31T21:56:56.000Z. Sources: 3. Developments: 2.

Lobe Sciences Ltd. has completed a two-tranche non-brokered private placement of common shares, raising a total of $2,160,000. The company issued 25,411,762 shares at a price of $0.085 per share.

The funds are intended for working capital, general corporate purposes, and the advancement of the S-100 drug candidate for the treatment of sickle cell disease. A portion of the proceeds will be allocated to its subsidiary, Applied Lipid Technologies, Inc., to support the S-100 program as it moves toward human clinical trials. The company confirmed it has already procured the active pharmaceutical ingredient necessary for these studies.

## Timeline

### 2026-08-31: Lobe Sciences raises $2.16 million for sickle cell drug development

Lobe Sciences has raised $2,160,000 through a private placement to fund its S-100 sickle cell disease drug candidate toward human clinical trials.

2 sources. https://clstr.news/cluster/lobe-sciences-raises-216-million-for-sickle-cell-drug-development

### 2026-08-29: Lobe Sciences upsizes private placement to fund sickle cell drug development

Lobe Sciences Ltd. is upsizing its non-brokered private placement to raise a total of approximately $2,160,000 to fund its S-100 sickle cell disease drug candidate development.

2 sources. https://clstr.news/cluster/lobe-sciences-upsizes-private-placement-to-fund-sickle-cell-drug-development

---
Cite as: Lobe Sciences sickle cell drug funding. CLSTR, https://clstr.news/situations/lobe-sciences-sickle-cell-drug-funding